




Research Paper

Hepatoprotective Effect of the Ethanolic Extract of *Moringa oleifera* Leaves in Carbon Tetrachloride-induced Wistar Rats

Annisa Dwi Lestari¹, R. Susanti^{1*}, Ari Yuniastuti¹

¹ Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Negeri Semarang, Semarang, Indonesia.



How to cite this paper:

Lestari AD, Susanti R, Yuniastuti A. Hepatoprotective Effect of the Ethanolic Extract of *Moringa oleifera* Leaves in Carbon Tetrachloride-induced Wistar Rats. *Iranian Journal of Toxicology*. 2026;20(-):---. doi: 10.32592/IJT.20.--.



doi: 10.32592/IJT.20.--



Article info

Received: 03/08/2025

Accepted: 29/10/2025

Online Published: 15/01/2026

* Corresponding author:

R. Susanti,

Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Negeri Semarang, Semarang, Indonesia.

E- mail: basanatha@mail.unnes.ac.id

ABSTRACT

Background: Hepatotoxicity is liver damage caused by exposure to xenobiotics, resulting when the liver is unable to detoxify free radicals, such as reactive oxygen species (ROS), or other harmful metabolites. *Moringa oleifera* has been reported to possess preventive and therapeutic potential against various diseases due to its extract and bioactive components, particularly quercetin, which plays a significant role in its hepatoprotective effects. The present study aimed to evaluate the hepatoprotective potential of ethanolic *Moringa oleifera* leaf extract in carbon tetrachloride (CCl₄)-induced rats.

Methods: A total of 25 male Wistar rats were divided into five groups: a negative control group (0.9% NaCl), a positive control group (CCl₄), and three treatment groups receiving *Moringa oleifera* extract at doses of 250 mg/kg body weight (D1), 500 mg/kg body weight (D2), and 1000 mg/kg body weight (D3), all previously induced with 10 % CCl₄ solution administered at 1 mL/kg body weight. Observations were made on aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels, as well as relative liver weight.

Results: Administration of ethanolic *Moringa oleifera* leaf extract at all three doses significantly reduced AST and ALT levels compared to the CCl₄ group, indicating hepatoprotective effects. However, no significant differences in relative liver weight were observed among the treatment groups.

Conclusion: Ethanolic *Moringa oleifera* leaf extract exhibits hepatoprotective effects against CCl₄-induced liver injury through the reduction of AST and ALT levels by 46.5% and 37%, respectively, although it does not influence relative liver weight.

Keywords: Alanine aminotransferase (ALT), Aminotransferase (AST), hepatoprotective, *Moringa oleifera*, Relative liver weight.

Introduction

The liver plays a crucial role in maintaining the body's homeostasis by participating in bilirubin and cholesterol metabolism, glucose synthesis and storage, hormone metabolism, plasma protein secretion, and detoxification of both endobiotics and xenobiotics [1, 2]. Xenobiotics are exogenous compounds introduced into the body through environmental exposure, including pollutants, toxic substances, and chemical agents [3]. These foreign compounds, which cannot be synthesized endogenously, are commonly found in consumer products, such as artificial colorants, preservatives, industrial chemicals, and pharmaceuticals [4].

Hepatotoxicity refers to liver injury or dysfunction caused by xenobiotic or drug exposure during hepatic metabolism [5]. This condition may arise from excessive drug consumption or exposure beyond therapeutic limits, potentially leading to harmful effects on the liver. Industrial chemicals like carbon tetrachloride (CCl₄),

widely used in laboratories and industries, are well-known hepatotoxins [6]. Impaired detoxification of free radicals, such as reactive oxygen species (ROS) and harmful metabolites, can result in liver damage [7]. Despite advances in medicine, no fully effective drugs are available to comprehensively enhance liver function, protect the organ, and facilitate hepatocyte regeneration. Therefore, exploring plant-based alternatives is essential to identify safer, more effective therapeutic agents for managing liver diseases [8].

Herbal medicines have long been used as primary healthcare in many cultures worldwide, offering bioactive compounds with therapeutic potential [9]. One such plant is *Moringa oleifera*, a species belonging to the genus *Moringa* (Family: Moringaceae), which thrives in tropical climates, including Indonesia. Almost all parts of *Moringa oleifera* (seeds, leaves, flowers, bark, roots, and fruits) contain diverse

bioactive components, including carotenoids, phenolics, alkaloids, glucosinolates, isothiocyanates, folates, tannins, saponins, and fatty acids. The primary phenolic constituents in *Moringa oleifera* leaves include flavonoids (e.g., quercetin, luteolin, myricetin, apigenin, and kaempferol), lignans, and phenolic acids (e.g., cumaroylquinic, caffeoylquinic, and feruloylquinic acids) [10]. These compounds contribute to various pharmacological properties, including antibacterial, anti-ulcer, antipyretic, antiepileptic, anticancer, and anti-inflammatory activities [11].

Of particular interest is the hepatoprotective effect of *Moringa oleifera*. Its phenolic and flavonoid compounds possess anti-inflammatory and antioxidant properties, preventing lipid peroxidation, reducing oxidative stress markers, and lowering liver enzyme levels [6]. Consequently, *Moringa oleifera* may protect the liver from oxidative stress caused by excessive free radical exposure.

Transaminases, intracellular enzymes released into circulation following cell injury, are commonly used as biomarkers of liver damage. Serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are extensively accepted indicators of liver injury, with elevated levels reflecting hepatocellular cytolysis [12, 13]. Additionally, changes in liver weight may indicate treatment-related alterations, such as hepatocellular hypertrophy caused by xenobiotic exposure [14].

The present study investigates the effects of *Moringa oleifera* leaf ethanolic extract on liver function parameters, including serum AST and ALT levels and relative liver weight, to provide evidence supporting its hepatoprotective potential.

Materials and Methods

Preparation of *Moringa oleifera* leaf extract

Fresh *Moringa oleifera* leaves were obtained from Tanjung Mas, Semarang, Central Java, Indonesia. Leaves were dried at 50°C and ground into powder. Extraction was performed by maceration using 70% ethanol as the solvent. The filtrate was concentrated with a rotary evaporator at 40°C until a thick extract was obtained, then oven-dried and reground before being dissolved according to the required doses.

Assessment of total flavonoid content (TFC) and total phenolic content (TPC)

The TFC was assessed using an aluminium chloride-based colorimetric assay. The sample extract was mixed with AlCl_3 reagent and incubated at room temperature, then the absorbance was measured at 430 nm against a reagent blank. Quercetin was used as the calibration standard, and TFC was expressed as milligrams of quercetin equivalent per gram extract (mg QE/g).

In addition, TPC was assessed using the Folin Ciocalteu colorimetric assay. The extract was mixed with Folin–Ciocalteu reagent and allowed to react briefly, after which a sodium carbonate solution was added. The mixture was incubated at room temperature, protected from light, and its absorbance was later recorded using a UV–Vis spectrophotometer at 765 nm. Gallic acid was employed to generate the calibration curve, and TPC was expressed as milligrams of gallic acid equivalents per gram of extract (mg GAE/g). The TFC and TPC were conducted at the Integrated Laboratory FMIPA, Universitas Negeri Semarang, Indonesia.

Preparation of CCl_4 solution

A 10% CCl_4 solution was prepared by mixing 0.4 mL of pure CCl_4 with 3.6 mL of mineral oil. The solution was administered at a dose of 1 mL/kg body weight, equivalent to 0.2 mL for a rat weighing approximately 200 g.

Experimental animals and treatments

A total of 25 male Wistar rats were acclimatized for seven days before being randomly assigned into five groups: normal control (K), positive control CCl_4 without extract (K^+), and three treatment groups receiving *Moringa oleifera* extract at doses of 250 (D1), 500 (D2), and 1000 (D3) mg/kg body weight.

Dose selection was guided by previously published studies demonstrating the hepatoprotective activity and safety of *Moringa oleifera* leaf extract within similar dose ranges in rat models. Previous toxicity evaluations indicated that *Moringa oleifera* leaf supplementation is safe at doses up to 1000 mg/kg body weight, whereas adverse effects appear at much higher levels, 3000 mg/kg body weight [15]. Within this established safe range, three doses were selected to evaluate potential dose-dependent hepatoprotective responses in the present study.

On day 1, CCl_4 was administered intraperitoneally. From the following day, the extract was given orally once daily for 14 consecutive days. All procedures were conducted in accordance with the guidelines of the Health Research Ethics Committee, Faculty of Medicine, Universitas Negeri Semarang, Indonesia, and approved under ethical clearance No. 263/KEPK/FK/KLE/2024.

Assessment of AST and ALT levels

On the last day, blood samples were collected via the orbital sinus and centrifuged to obtain serum. The AST and ALT levels were measured using Diasys® enzymatic kits ASAT (GOT) FS (Cat. No. 1 2601 99 10 021) and ALAT (GPT) FS (Cat. No. 1 2701 99 10 021), read with a UV–Vis spectrophotometer at a

wavelength of 340 nm in the Laboratory of the Centre for Food and Nutrition Studies, Universitas Gadjah Mada, Indonesia.

Relative liver weight analysis

On day 16, rats were euthanized, and the liver was excised, cleaned, and weighed using a digital analytical balance. Relative liver weight (RLW) was calculated as:

$$RLW = \frac{\text{absolute organ weight (g)}}{\text{body weight at sacrifice (g)}} \times 100$$

Data analysis

Relative liver weights were calculated using Microsoft Excel. The AST and ALT measurements were performed at the Laboratory of the Center for Food and Nutrition Studies, Universitas Gadjah Mada, Indonesia. Moreover, the Shapiro–Wilk test was employed to assess normality, and Levene’s test was used for homogeneity of variance in IBM SPSS Statistics (version 27) software. Parametric data were analyzed by one-way ANOVA followed by Tukey’s post-hoc test, while non-parametric data were

analyzed using the Kruskal–Wallis test followed by the Mann–Whitney U test to determine significant differences between groups. The TFC and TPC were analyzed once as descriptive parameters at the Integrated Laboratory FMIPA, Universitas Negeri Semarang. Statistical analysis was not performed on TFC and TPC data, as these represent single-value determinations of extract characteristics.

Results

Total phenolic and flavonoid content of *Moringa oleifera* leaf ethanolic extract

The phytochemical characterization of the *Moringa oleifera* leaf ethanolic extract confirmed measurable levels of TFC and high levels of TPC. The extract contained 8.84 mg QE/g sample of TFC and 110 mg GAE/g sample of TPC (Table 1). Following the extract characterization, statistical analysis for the biological parameters was then carried out, beginning with the assessment of data normality.

Table 1. Phytochemical characterization of *Moringa oleifera* leaf extract

Parameter	Value	Unit
Total Flavonoid Content (TFC)	8.84	mg QE/g extract
Total Phenolic Content (TPC)	110	mg GAE/g extract

Effect of *moringa oleifera* leaf ethanolic extract on AST levels in CCl₄-induced rats

The Shapiro–Wilk normality test indicated that AST levels were normally distributed ($p > 0.05$), and Levene’s homogeneity test showed homogeneous variance ($p = 0.161$). According to these results, the analysis was continued using one-way ANOVA, which demonstrated

significant differences between groups ($p < 0.001$). The Tukey post-hoc test indicated that the control group (K) differed significantly from all treatment groups, with the most pronounced difference compared to the positive control group (K+). Among the treatment groups, the K+ group differed most significantly from the D3 group. The comparison of AST levels between groups is shown in Table 2.

Table 2. Analysis results of AST levels

Group	Mean±Standard Deviation (SD)	Normality Test	Homogeneity Test	ANOVA Test
K	37.29±0.63 ^a	0.425		
K+	79.53±1.26 ^e	0.503		
D1	50.30±0.73 ^d	0.498	0.161	<0.001
D2	45.25±1.21 ^c	0.386		
D3	42.53±0.55 ^b	0.819		

Note: Values followed by different superscript letters (a, b, c, d, e) indicate significant differences.

Effect of *moringa oleifera* leaf ethanolic extract on ALT levels in CCl₄-induced rats

The ALT levels were normally distributed according to the Shapiro–Wilk test; however, the Levene test indicated that the data were not homogeneous ($p < 0.05$). Therefore, the analysis was continued using the non-parametric Kruskal–Wallis test. The results revealed significant

differences between groups ($p < 0.05$). The Mann–Whitney U test showed significant differences between several group pairs ($p < 0.05$). Descriptive analysis indicated that among the treatment groups, the D3 group had the lowest ALT level (24.76 U/L), which was close to that of the control group (K) (19.32 U/L), as shown in Table 3.

Table 3. Analysis results of ALT levels

Group	Mean±Standard Deviation (SD)	Normality Test	Homogeneity Test	Kruskal-Wallis Nonparametric Test
K	19.32±0.41 ^a	0.314		
K+	39.32±1.88 ^c	0.533		
D1	30.30±0.74 ^d	0.487	0.001	<0.001
D2	27.96±0.55 ^c	0.809		
D3	24.76±1.14 ^b	0.153		

Note: Values followed by different superscript letters (a, b, c, d, e) indicate significant differences.

Effect of *moringa oleifera* leaf ethanolic extract on relative liver weight in CCl₄-induced rats

Relative liver weight data were homogeneous based on Levene's test, but not all data were normally distributed

according to the Shapiro–Wilk test ($p < 0.05$). Therefore, the analysis continued with the Kruskal–Wallis test, which showed no significant differences between the treatment groups ($p > 0.05$, Table 4).

Table 4. Analysis Results of Relative Liver Weight

Group	Mean±Standard Deviation (SD)	Normality Test	Homogeneity Test	Kruskal-Wallis Nonparametric Test
K	3.86±0.54 ^a	0.040		
K+	3.92±0.23 ^a	0.265		
D1	3.92±0.27 ^a	0.815	0.332	0.078
D2	4.11±0.42 ^a	0.120		
D3	4.50±0.33 ^a	0.606		

Note: Values followed by the same superscript letter (a) indicate no significant difference.

Discussion

Hepatotoxicity can result from the entry of xenobiotic compounds, such as drugs at toxic doses or industrial chemicals like CCl₄, into the body. In this study, CCl₄ was used to induce liver injury by intraperitoneal injection in male Wistar rats.

The AST and ALT serve as key biomarkers to assess liver function and detect hepatocellular injury. While AST is found in multiple tissues, ALT is predominantly cytosolic and liver-specific. Hepatic injury leads to the release of these enzymes into circulation, with their serum levels correlating with the extent of tissue damage [16, 17]. In addition to enzyme elevation, liver injury can cause morphological changes, such as increased relative liver weight.

The AST and ALT levels demonstrated a significant rise in the CCl₄ only group (K⁺) compared with the control (K) (Tables 2 and 3). Although values remained within the normal range for rats, the two- to three-fold increase in ALT suggests hepatocellular damage [18]. These findings are consistent with previous studies indicating that CCl₄ administration elevates transaminase levels [19, 20]. In contrast, relative liver weight did not differ significantly between groups (Table 4).

Moringa oleifera leaves contain potent antioxidants, including quercetin, kaempferol, ascorbic acid, β -carotene, isothiocyanates, polyphenols, and rutin, which can be efficiently extracted with 70% ethanol [21, 22].

Phenolic compounds identified in the extract include p-hydroxybenzoic acid, sinapic acid, caffeic acid, gallic acid, and others, while flavonoids like catechin, rutin, and quercetin are among the most bioactive constituents [23].

Administration of *Moringa oleifera* leaf ethanolic extract significantly reduced serum AST and ALT levels ($p < 0.001$), with enzyme activities approaching control values, suggesting hepatoprotective effects (Table 3). This protective action is probably due to the diverse bioactive compounds present in the extract. Similar hepatoprotective effects have been reported in acetaminophen-induced toxicity models, in which *Moringa oleifera* leaf extract improved histopathology and reduced liver enzymes [24]. Additionally, *Moringa oleifera* leaf extract reduced ALT, AST, and ALP levels in cadmium chloride-induced hepatotoxicity [25].

Relative liver weight increased in the CCl₄ and treatment groups, but without statistical significance (Table 4). This increase may reflect the accumulation of fat or glycogen, or hepatocellular hypertrophy or hyperplasia as an adaptive response to injury [26]. Hepatocellular hypertrophy following xenobiotic exposure is a reversible, non-adverse change, especially in the absence of necrosis or elevated ALT [27]. Therefore, liver weight changes in treated groups likely represent a metabolic adaptation rather than damage.

Although *in vivo* oxidative stress markers (e.g., MDA, SOD, or GSH) were not directly quantified in this study, the mechanism of hepatoprotection is strongly suggested to be antioxidant-mediated. The CCl₄ induces toxicity primarily through the generation of free radicals [28, 29]. The phytochemical analysis in this study revealed a high TPC of 110 mg GAE/g and a measurable TFC of 8.84 mg QE/g (Table 1). The TPC value obtained in this study was higher than that reported in a previous study by [30], which observed 55.97±3.10 mg GAE/g in a leaf ethanolic extract of *Moringa oleifera*. However, the TFC value was slightly lower than their reported 11.30±0.06 mg QE/g. Another study by [31] reported a TFC value of 7.79 mg QE/g for a *Moringa oleifera* leaf water extract, which is slightly lower than the TFC value obtained in this study. This variation in phytochemical content emphasises the importance of considering extract characteristics when assessing the physiological impact.

Phenolic compounds are well-documented to act as potent free radical scavengers [32]. Therefore, the significant reduction in AST and ALT levels observed is likely attributed to the antioxidant capacity of the high phenolic concentration in the extract, which counteracts the oxidative cascade initiated by CCl₄. In addition, flavonoids have been broadly reported to exert hepatoprotective effects through their anti-inflammatory and antioxidant properties, including the ability to reduce hepatic inflammation, suppress oxidative stress, and stabilize hepatocyte membranes, thereby preventing the leakage of liver enzymes, such as AST and ALT, into circulation [33, 34]. Consistent with previous findings, higher levels of phenolics and flavonoids in plant extracts are frequently associated with stronger antioxidant and anti-inflammatory activities [34, 35].

The highest dose of *Moringa oleifera* leaf ethanolic extract of 1000 mg/kg body weight (D3) produced the most significant hepatoprotective effect, as evidenced by substantial reductions in serum AST and ALT activities (Tables 2 and 3). Compared with the CCl₄-only treated group (K+), AST and ALT of the D3 group decreased by 46.5% and 37%, respectively, indicating liver function toward normal control values (K); this dose is considered safe and non-genotoxic [36].

Conclusions

Administration of *Moringa oleifera* ethanolic extract significantly reduced serum AST and ALT levels in Wistar rats induced with 10 % CCl₄ solution administered at 1 mL/kg body weight. The optimal results were observed in the D3 group (1000 mg/kg body weight), with AST and ALT levels decreased by 46.5% and 37%, respectively, compared to the CCl₄-only-treated group (K+). However, the administration of *Moringa oleifera* ethanolic extract did not significantly affect the relative liver weight in rats exposed to CCl₄.

Data Access and Responsibility

The authors confirm that this article contains original work and accept full responsibility for its content.

Ethical Considerations

All experimental procedures involving animals were approved by the Ethics Committee of Universitas Negeri Semarang, No. 263/KEPK/FK/KLE/2024.

Authors' Contributions

ADL: Conducted experiments, data collection, data analysis, and manuscript drafting. RS: Supervised the research, provided guidance on methodology, data analysis, and manuscript review.

AY: Supervised the research, assisted in the general idea, data analysis, and manuscript review.

Acknowledgement

The authors would like to extend their sincere gratitude to the Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Negeri Semarang, Indonesia, for providing laboratory facilities and support. This manuscript is derived from the Bachelor's project of Annisa Dwi Lestari, submitted in partial fulfillment of the requirements for the Bachelor of Science degree in Biology at Universitas Negeri Semarang.

Conflict of Interests

The authors declare that there is no conflict of interest.

Funding

Private.

References

1. Berasain C, Arechederra M, Argemí J, Fernández-Barrena MG, Avila MA. Loss of liver function in chronic liver disease: an identity crisis. *J Hepatol.* 2023;**78**(2):401-14. [DOI:10.1016/j.jhep.2022.09.001] [PMID: 36115636]
2. Chaudhary S, Gupta RK, Gupta MK, Verma HC, Kumar H, Kumar A, et al. Hepatoprotective response of *Cordia sebestena* L. fruit against simvastatin induced hepatotoxicity. *J Pharm Pharmacognosy Res.* 2020;**8**(4):327-35. [DOI:10.56499/jppres20.799 8.4.327]
3. Pal S, Firdous SM. Unraveling the role of heavy metals xenobiotics in cancer: a critical review. *Discov Oncol.* 2024;**15**(1):615. [DOI:10.1007/s12672-024-01417-y] [PMID:39495398]
4. Alnasser SM. From gut to liver: organoids as platforms for next-generation toxicology assessment vehicles for xenobiotics. *Stem Cell Res Ther.* 2025;**16**(1):150. [DOI:10.1186/s13287-025-04264-y] [PMID: 40140938]
5. Chen P, Zou F, Liu W. Recent advancement in prevention against hepatotoxicity, molecular mechanisms, and bioavailability of gallic acid, a natural phenolic compound: challenges and perspectives. *Front Pharmacol.* 2025;**16**:1549526. [DOI:10.3389/fphar.2025.1549526] [PMID: 40191418]
6. Sowunmi BO, Gonzo M. The effect of *Moringa oleifera* crude extract on liver cell line, HepG2. *BMC Complement Med Ther.*

- 2023;**23**(1):380. [DOI:10.1186/s12906-023-04181-8] [PMID:37884920]
7. Codorniz KD, Emielle Marquina RM, Dominique Nolasco AG, Denise Palencia PD, Mata SB. Evaluation of the hepatoprotective effect of methanolic extract of *Caulerpa lentillifera* against acetaminophen-induced liver toxicity in juvenile zebrafish (*Danio rerio*). *J Ilm Farm*. 2020;**16**(1):31-8. [DOI:10.20885/jif.vol16.iss1.art4]
8. Datta S, Aggarwal D, Sehrawat N, Yadav M, Sharma V, Sharma A, et al. Hepatoprotective effects of natural drugs: current trends, scope, relevance and future perspectives. *Phytomedicine*. 2023;**121**:155100. [DOI: 10.1016/j.phymed.2023.155100] [PMID: 37801892]
9. Wang H, Chen Y, Wang L, Liu Q, Yang S, Wang C. Advancing herbal medicine: enhancing product quality and safety through robust quality control practices. *Front Pharmacol*. 2023;**14**:1265178. [DOI:10.3389/fphar.2023.1265178] [PMID: 37818188]
10. Pop OL, Kerezsi AD, Ciont C. A comprehensive review of *Moringa oleifera* bioactive compounds—cytotoxicity evaluation and their encapsulation. *Foods*. 2022;**11**(23):3787. [DOI:10.3390/foods11233787] [PMID: 36496595]
11. Rathore J, Das CR. *Moringa oleifera*: a review of phytochemicals constituents and medicinal properties as a future source of new drugs. *Int J Health Sci*. 2022;**6**(1):6952-76. [DOI:10.53730/ijhs.v6nS1.6471]
12. Curci F, Stinco M, Carrera S, Rubino C, Indolfi G. Diagnostic approach for children with increased serum concentrations of aminotransferases. *Glob Pediatr*. 2024;**7**:100118. [DOI:10.1016/j.gpeds.2023.100118]
13. Music M, Dervisevic A, Pepic E, Lepara O, Fajkic A, Ascic-Buturovic B, et al. Metabolic syndrome and serum liver enzymes level at patients with type 2 diabetes mellitus. *Med Arch*. 2015;**69**(4):251-5. [DOI: 10.5455/medarh.2015.69.251-255] [PMID: 26543313]
14. Sellers RS, Morton D, Michael B, Roome N, Johnson JK, Yano BL, et al. Society of toxicologic pathology position paper: organ weight recommendations for toxicology studies. *Toxicol Pathol*. 2007;**35**(5):751-5. [DOI:10.1080/01926230701595300] [PMID:17849358]
15. Asare GA, Gyan B, Bugyei K, Adjei S, Mahama R, Addo P, et al. Toxicity potentials of the nutraceutical *Moringa oleifera* at supra-supplementation levels. *J Ethnopharmacol*. 2012;**139**(1):265-72. [DOI: 10.1016/j.jep.2011.11.009] [PMID: 22101359]
16. Oh RC, Hustead TR, Ali SM, Pantsari MW. Mildly elevated liver transaminase levels: causes and evaluation. *Am Fam Physician*. 2017;**96**(11):709-15. [PMID: 29431403]
17. Hasan KMM, Tamanna N, Haque MA. Biochemical and histopathological profiling of Wistar rat treated with *Brassica napus* as a supplementary feed. *Food Sci Hum Wellness*. 2018;**7**(1):77-82. [DOI: 10.1016/j.fshw.2017.12.002]
18. Hall AP, Elcombe CR, Foster JR, Harada T, Kaufmann W, Knippel A, et al. Liver hypertrophy: a review of adaptive (adverse and non-adverse) changes—conclusions from the 3rd international ESTP expert workshop. *Toxicol Pathol*. 2012;**40**(7):971-94. [DOI: 10.1177/0192623312448935] [PMID: 22723046]
19. Alkinani KB, Ali EMM, Al-Shaikh TM, Awlia Khan JA, Al-Naomasi TM, Ali SS, et al. Hepatoprotective effects of (-) epicatechin in CCl₄-induced toxicity model are mediated via modulation of oxidative stress markers in rats. *Evid Based Complement Alternat Med*. 2021;**2021**:4655150. [DOI: 10.1155/2021/4655150] [PMID: 3497609]
20. Mahmoodzadeh Y, Mazani M, Rezagholizadeh L. Hepatoprotective effect of methanolic *Tanacetum parthenium* extract on CCl₄-induced liver damage in rats. *Toxicol Rep*. 2017;**4**:455-62. [DOI: 10.1016/j.toxrep.2017.08.003] [PMID: 28959674]
21. Kashyap P, Kumar S, Riar CS, Jindal N, Baniwal P, Guiné RPF, et al. Recent advances in drumstick (*Moringa oleifera*) leaves bioactive compounds: composition, health benefits, bioaccessibility, and dietary applications. *Antioxidants*. 2022;**11**(2):402. [DOI:10.3390/antiox11020402] [PMID: 35204283]
22. Chaves JO, De Souza MC, Da Silva LC, Lachos-Perez D, Torres-Mayanga PC, Machado APF, et al. Extraction of flavonoids from natural sources using modern techniques. *Front Chem*. 2020;**8**:507887. [DOI: 10.3389/fchem.2020.507887] [PMID: 33102442]
23. Aly O, Abouelfadl DM, Shaker OG, Hegazy GA, Fayed AM, Zaki HH. Hepatoprotective effect of *Moringa oleifera* extract on TNF- α and TGF- β expression in acetaminophen-induced liver fibrosis in rats. *Egypt J Med Hum Genet*. 2020;**21**(1):69. [DOI:10.1186/s43042-020-00106-z]
24. Fakurazi S, Hairuzah I, Nanthini U. *Moringa oleifera* lam prevents acetaminophen induced liver injury through restoration of glutathione level. *Food Chem Toxicol*. 2008;**46**(8):2611-15. [DOI: 10.1016/j.fct.2008.04.018] [PMID: 18514995]
25. Aladeyu SO, Onyejike DN, Ogundairo OA, Adeoye OA, Gbadamosi MT, Ogunlade B, Ojewale AO. Hepatoprotective role of *Moringa oleifera* ethanolic leaf extract on liver functions (biomarkers) in cadmium chloride-induced hepatotoxicity in albino Wistar rats. *Int J Basic Appl Innov Res*. 2018;**7**(1):12–17. [LINK]
26. Greaves P. Liver and pancreas. *Histopathol Preclin Toxicol Stud*. 2007;**457**:569. [DOI: 10.1016/B978-044452771-4/50010-9]
27. Palazzi X, Burkhardt JE, Caplain H, Dellarco V, Fant P, Foster JR, et al. Characterizing “adversity” of pathology findings in nonclinical toxicity studies: results from the 4th ESTP international expert workshop. *Toxicol Pathol*. 2016;**44**(6):810-24. [DOI: 10.1177/0192623316642527] [PMID: 27102650]
28. Munir F, Khan MKA. Hepatotoxicity induced by carbon tetrachloride in experimental model. *Pak Biomed J*. 2023;**6**(7):10-5. [DOI: 10.54393/pbmj.v6i07.900]
29. Algefare AI, Alfwuaires M, Famurewa AC, Elsayy H, Sedky A. Geraniol prevents CCl₄-induced hepatotoxicity via suppression of hepatic oxidative stress, pro-inflammation and apoptosis in rats. *Toxicol Rep*. 2024;**12**:128-34. [DOI:10.1016/j.toxrep.2024.01.007] [PMID: 38304701]
30. Ubah PC, Dashti AF, Saaïd M, Imam SS, Adnan R. Fabrication and response optimization of *Moringa oleifera*-functionalized nanosorbents for the removal of diesel range organics from contaminated water. *Environ Sci Pollut Res Int*. 2023;**30**(2):4462-84. [DOI: 10.1007/s11356-022-22245-z] [PMID: 35969341]
31. Pradana DLC, Wulandari AA. Uji total flavonoid dari ekstrak air daun kelor (*Moringa oleifera*) dan secang (*Caesalpinia sappan* L.). *J Insan Farm Indones*. 2019;**2**(2):271-7. [DOI:10.36387/jifi.v2i2.407]
32. Arshad MT, Maqsood S, Ikram A, Gnedeka KT. Recent perspectives on the pharmacological, nutraceutical, functional, and therapeutic properties of *Moringa oleifera* plant. *Food Sci Nutr*. 2025;**13**(4):e70134. [DOI: 10.1002/fsn.70134] [PMID: 40248126]
33. Sokal-Dembowska A, Jarmakiewicz-Czaja S, Filip R. Flavonoids and their role in preventing the development and progression of MAFLD by modifying the microbiota. *Int J Mol Sci*. 2024;**25**(20):11187. [DOI:10.3390/ijms252011187] [PMID:39456969]
34. Sun W, Shahrajabian MH. Therapeutic potential of phenolic compounds in medicinal plants: natural health products for human health. *Mol*. 2023;**28**(4):1845. [DOI:10.3390/molecules28041845] [PMID:36838831]
35. Khanam A, Ahmad A, Iftikhar N, Ali Q, Fatima T, Alswailmi FK, et al. Variation in phenolic profile, antioxidant, and anti-inflammatory activities of *Salvadora oleoides* Decne. and *Salvadora persica* L. fruits and aerial part extracts. *Life*. 2022;**12**(9):1446. [DOI:10.3390/life12091446] [PMID:36143482]
36. Stohs SJ, Hartman MJ. Review of the safety and efficacy of *Moringa oleifera*. *Phytother Res*. 2015;**29**(6):796-804. [DOI:10.1002/ptr.5325] [PMID: 25808883]